Spectrum and Classification of Inflammatory Demyelinating Diseases of the Central Nervous System

Overview

Journal Curr Neurol Neurosci Rep

Specialty Neurology

Date 2002 Mar 20

PMID 11898526

Citations 2

Authors

B Kalman

F D Lublin

Affiliations

Soon will be listed here.

Abstract

The aim of this review is to highlight recent observations concerning the pathogenesis of acute and chronic inflammatory demyelinating diseases in the central nervous system. Without attempting to provide a didactic classification or a complete survey, we emphasize the discriminative nature of new clinical, imaging, and immunopathologic data, which, even in the absence of specific molecular markers, modify our views about the nosologic relations among these overlapping clinicopathologic entities. In the light of new findings, multiple sclerosis may represent a spectrum of demyelinating diseases rather than a single entity.

Citing Articles

Peripheral third cranial nerve enhancement in multiple sclerosis.

Bhatti M, Schmalfuss I, Williams L, Quisling R AJNR Am J Neuroradiol. 2003; 24(7):1390-5.

PMID: 12917135 PMC: 7973702.

Cognitive impairments in multiple sclerosis: a review.

DeSousa E, Albert R, Kalman B Am J Alzheimers Dis Other Demen. 2002; 17(1):23-9.

PMID: 11831417 PMC: 10833971. DOI: 10.1177/153331750201700104.

References

Truyen L, van Waesberghe J, van Walderveen M, van Oosten B, Polman C, Hommes O . Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology. 1996; 47(6):1469-76. DOI: 10.1212/wnl.47.6.1469. View

Mandler R, Davis L, Jeffery D, Kornfeld M . Devic's neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol. 1993; 34(2):162-8. DOI: 10.1002/ana.410340211. View

Narayanan S, Fu L, Pioro E, De Stefano N, Collins D, Francis G . Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol. 1997; 41(3):385-91. DOI: 10.1002/ana.410410314. View

Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H . Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000; 47(6):707-17. DOI: 10.1002/1531-8249(200006)47:6<707::aid-ana3>3.0.co;2-q. View

Baranzini S, Jeong M, Butunoi C, MURRAY R, Bernard C, Oksenberg J . B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol. 1999; 163(9):5133-44. View

Campi A, Filippi M, Comi G, Scotti G . Recurrent acute transverse myelopathy associated with anticardiolipin antibodies. AJNR Am J Neuroradiol. 1998; 19(4):781-6. PMC: 8337417. View

Karussis D, Leker R, Ashkenazi A, Abramsky O . A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity?. Ann Neurol. 1998; 44(4):629-34. DOI: 10.1002/ana.410440408. View

Silver N, Lai M, Symms M, Barker G, McDonald W, Miller D . Serial magnetization transfer imaging to characterize the early evolution of new MS lesions. Neurology. 1998; 51(3):758-64. DOI: 10.1212/wnl.51.3.758. View

Lublin F, Reingold S . Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996; 46(4):907-11. DOI: 10.1212/wnl.46.4.907. View

10.

Kerschensteiner M, Gallmeier E, Behrens L, Leal V, Misgeld T, Klinkert W . Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?. J Exp Med. 1999; 189(5):865-70. PMC: 2192942. DOI: 10.1084/jem.189.5.865. View

11.

Goodkin D, Rooney W, Sloan R, Bacchetti P, Gee L, Vermathen M . A serial study of new MS lesions and the white matter from which they arise. Neurology. 1998; 51(6):1689-97. DOI: 10.1212/wnl.51.6.1689. View

12.

Richert N, Frank J . Magnetization transfer imaging to monitor clinical trials in multiple sclerosis. Neurology. 1999; 53(5 Suppl 3):S29-32. View

13.

Russell J, Cross A . Role of Fas--FasL interactions in the pathogenesis and regulation of autoimmune demyelinating disease. J Neuroimmunol. 2000; 100(1-2):42-52. DOI: 10.1016/s0165-5728(99)00191-5. View

14.

Cuadrado M, Khamashta M, Ballesteros A, Godfrey T, Simon M, Hughes G . Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine (Baltimore). 2000; 79(1):57-68. DOI: 10.1097/00005792-200001000-00006. View

15.

Davie C, Silver N, Barker G, Tofts P, Thompson A, McDonald W . Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup?. J Neurol Neurosurg Psychiatry. 1999; 67(6):710-5. PMC: 1736689. DOI: 10.1136/jnnp.67.6.710. View

16.

Filippi M, Rocca M, Moiola L, Martinelli V, Ghezzi A, Capra R . MRI and magnetization transfer imaging changes in the brain and cervical cord of patients with Devic's neuromyelitis optica. Neurology. 1999; 53(8):1705-10. DOI: 10.1212/wnl.53.8.1705. View

17.

von Muhlen C, Tan E . Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum. 1995; 24(5):323-58. DOI: 10.1016/s0049-0172(95)80004-2. View

18.

Cercignani M, Iannucci G, Rocca M, Comi G, Horsfield M, Filippi M . Pathologic damage in MS assessed by diffusion-weighted and magnetization transfer MRI. Neurology. 2000; 54(5):1139-44. DOI: 10.1212/wnl.54.5.1139. View

19.

Pitt D, Werner P, Raine C . Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med. 1999; 6(1):67-70. DOI: 10.1038/71555. View

20.

Kira J, Kanai T, Nishimura Y, Yamasaki K, Matsushita S, Kawano Y . Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders. Ann Neurol. 1996; 40(4):569-74. DOI: 10.1002/ana.410400405. View